Abstract
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are active against the commonly occurring mutations of HIV are urgently needed for the treatment of AIDS. We synthesized new NNRTIs of the indolyl aryl sulphone (IAS) family, which are endowed with high antiviral potency against HIV-1 wt (wild-type), and the Y181C and K103N-Y181C drug resistant mutant strains. Several new compounds were highly active in lymphocytes infected with primary isolates carrying the K103N-V108I-M184V and L100I-V108I mutations. The design of new IASs was based on three-dimensional quantitative structure-activity relationship (3D QSAR) studies and docking simulations. A cross-docking study was also undertaken to gain some insights in to the binding mode of the newly synthesized IASs in the wt and mutated isoforms of reverse transcriptase. ©2006 International Medical Press.
Author supplied keywords
Cite
CITATION STYLE
De Martino, G., La Regina, G., Ragno, R., Coluccia, A., Bergamini, A., Ciaprini, C., … Silvestri, R. (2006). Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: Synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antiviral Chemistry and Chemotherapy, 17(2), 59–77. https://doi.org/10.1177/095632020601700202
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.